GlassScriptPhysician profile
Ian Santoro
NPI 1952395469
$10,900.10
in general payments reported to CMS, 2019-2025
25 companies · $1,862 in 2025
The $1,862 reported for 2025 was more than what 82% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,064 · 2020: $520 · 2021: $731 · 2022: $3,301 · 2023: $1,506 · 2024: $917 · 2025: $1,862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,285.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,437.49 | 2019-2025 | Aveir, Gallant, Jot Dx |
| Boston Scientific Corporation | $2,771.45 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Resonate El Icd Vr, Rhythmia Mapping System |
| Aop Health US, LLC | $979.72 | 2025 | Rapiblyk |
| Cvrx, INC. | $605.46 | 2021-2025 | Barostim Neo System |
| Medtronic, INC. | $504.35 | 2021-2025 | Micra, Mycarelink, Plasmablade(Tm) |
| Novartis Pharmaceuticals Corporation | $422.62 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $148.93 | 2021-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $147.43 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $139.13 | 2019-2025 | Camzyos |
| W. L. Gore & Associates, INC. | $138.24 | 2024 | Gore Cardioform Septal Occluder |
| Biosense Webster, INC. | $108.23 | 2021 | |
| Sanofi-Aventis U.S. LLC | $88.90 | 2019-2023 | |
| Pfizer INC. | $80.34 | 2019-2024 | |
| Medtronic Vascular, INC. | $63.10 | 2019 | |
| Altathera Pharmaceuticals LLC | $52.40 | 2023 | Sotalol Hydrochloride |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $45.89 | 2024 | Venclose Maven Catheter |
| Regeneron Healthcare Solutions, INC. | $31.80 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $25.51 | 2022-2023 | Arcalyst |
| Esperion Therapeutics, INC. | $20.42 | 2022 | |
| Novo Nordisk INC | $18.31 | 2022 | |
| Chiesi USA, INC. | $16.35 | 2020 | |
| Kiniksa Pharmaceuticals International, Plc | $15.89 | 2024 | Arcalyst |
| B. Braun Interventional Systems INC. | $12.97 | 2023 | No Marketed Product Name |
| Astrazeneca Pharmaceuticals LP | $12.80 | 2019 | |
| Amgen INC. | $12.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ian Santoro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.